TENNESSEE GENERAL ASSEMBLY FISCAL REVIEW COMMITTEE



FISCAL MEMORANDUM

HB 686 - SB 980

March 7, 2022

SUMMARY OF BILL AS AMENDED (015087): Authorizes the chief medical officer (CMO) to implement a statewide collaborative pharmacy practice agreement specific to dispensing epinephrine auto-injectors (epi-pens) with any licensed practicing pharmacist. Authorizes pharmacist to dispense epi-pens in certain circumstances such as to a person at risk of experiencing a severe allergic reaction that would require the use of an epi-pen; or to a family member, friend, or other person in a position to assist a person at risk of experiencing a severe allergic reaction requiring the use of an epi-pen.

FISCAL IMPACT OF BILL AS AMENDED:

Increase State Expenditure – \$262,900/FY22-23 and Subsequent Years

Increase Federal Expenditures – \$514,000/FY22-23 and Subsequent Years

Assumptions for the bill as amended:

- Based on information provided by the Division of TennCare (Division), the Division dispensed 14,320 epi-pens in 2020, at an average prescription cost of \$217.
- Implementing a statewide collaborative pharmacy practice agreement specific to dispensing epi-pens is reasonably assumed to increase the number of epi-pens dispensed by an estimated 25 percent, or 3,580 (14,320 x 25.0%).
- The increase in expenditures is estimated to be \$776,860 (3,580 epi-pens x \$217).
- Medicaid expenditures receive matching funds at a rate of 66.165 percent federal funds to 33.835 percent state funds. Of this amount \$262,851 (\$776,860 x 33.835%) will be in state funds and \$514,009 (\$776,860 x 66.165%) will be in federal funds in FY22-23 and subsequent years.
- The Department of Health (DOH) clinics do not dispense or issue epinephrine autoinjector products to patients; therefore, any fiscal impact to the DOH is estimated to be not significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

Krista Lee Carsner, Executive Director

Kista Les Caroner

/jw